FibroBiologics, Inc. Common Stock
Support and Resistance Levels
Past performance
News About FBLG
All events for FBLG
All deals for FBLG
Financial Ratios
Financial Statements
FBLG vs Sector & Peers
About FibroBiologics, Inc. Common Stock
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas. Website fibrobiologics.com
Headquarters Houston, TX, US